QurieGen is a technology company.
QurieGen has raised $2.0M across 1 funding round.
QurieGen has raised $2.0M in total across 1 funding round.
QurieGen B.V. is a Dutch biotech startup spun out from Radboud University in Nijmegen, specializing in single-cell sequencing technology to accelerate and de-risk drug discovery.[1][2][3] Its core product, QuRIE-seq, simultaneously maps transcriptome, membrane proteins, intracellular proteins, and phosphoproteins, enabling high-resolution predictive models of disease biology and drug responses through systems biology, data science, and AI.[1][2][3] The company serves pharma R&D teams by providing quantitative mode-of-action (MoA) insights across pathways and timescales, solving key challenges like understanding cellular heterogeneity, toxicity, resistance, and patient responses to streamline discovery, pre-clinical, and clinical stages.[2][3] Early growth includes pilot projects with Aduro Biotech, Janssen Pharmaceutica (J&J), and Acerta Pharma (AstraZeneca), plus a €2.2 million pre-seed raise to advance its AI-driven platform.[2][5]
QurieGen emerged as a spin-off from Radboud University, founded by a trio of experts: Dr. Eng. Kinga Matuła (CEO), Dr. Francesca Rivello (CSO), and Prof. Dr. Wilhelm Huck (board member), a serial entrepreneur behind Sphere Fluidics and Cytofind Diagnostics, and Spinoza Prize winner.[1][2] The idea stemmed from pioneering a patented single-cell method (IP filed) to capture dynamic cellular responses—overlooked by competitors lacking phosphoproteome data—pivoting from academic research to commercial pilots.[2][3] Key early traction came via paid collaborations with major pharma players like Aduro Biotech (Oss), Janssen (Beerse), and Acerta Pharma (Oss), validating its tech and fueling a €2.2 million pre-seed round in 2025 to scale AI integration.[2][5]
(Note: One source describes focus on diagnostic kits/genetic testing[4], but primary evidence confirms drug discovery platform[1][2][3][5].)
QurieGen rides the AI-systems biology wave in biotech, where single-cell multi-omics meets machine learning to tackle drug discovery's 90% failure rate amid rising costs (>$2B per drug).[3] Timing aligns with post-2020 AI booms (e.g., AlphaFold) and single-cell tech maturation, amplified by pharma's push for precision medicine amid aging populations and resistance crises.[2][3] Market tailwinds include € billions in EU DeepTech funding and demand for de-risking tools, as traditional methods falter on cellular complexity.[5] It influences the ecosystem by enabling data-driven target ID and combos, potentially cutting timelines 20-50% and fostering open biology insights via pharma partnerships.[1][2]
Next steps center on expanding paid pilots into service contracts, leveraging €2.2M to refine AI models and target high-need areas like oncology/immunology.[2][5] Trends like multimodal single-cell AI and real-world evidence integration will amplify its edge, with long-term potential in novel target discovery and patient stratification tools.[2][3] Influence may grow via more Big Pharma tie-ups or follow-on funding, evolving from service provider to platform leader—ultimately revolutionizing how we decode biology to deliver effective treatments faster.[1][3] This positions QurieGen as a high-momentum player de-risking the next drug discovery era.
QurieGen has raised $2.0M in total across 1 funding round.
QurieGen's investors include Andreessen Horowitz, Draper Associates.
QurieGen has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $2.0M Seed | Andreessen Horowitz, Draper Associates |